1)Kwong JC, Schwartz KL, Campitelli MA, et al:Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 378:345-353,2018
2)日本ワクチン産業協会:予防接種に関するQ&A集(2021年版)(http://www.wakutin.or.jp/medical/index.html#book01)(最終アクセス:2022年3月9日)
3)Ikeno D, Kimachi K, Kino Y, et al:Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol 54:81-88,2010
4)Reichert TA, Sugaya N, Fedson DS, et al:The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344:889-896,2001
5)Cate TR, Couch RB, Parker D, et al:Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines -1978. Rev Infect Dis 5:737-747,1983
6)Centers for Disease Control and Prevention (CDC):The Pink Book Home. Epidemiology and Prevention of Vaccine-Preventable Diseases. Chapter 12: Influenza(https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html)(最終アクセス:2022年2月27日)
7)Fiore AE, Bridges CB, Katz JM, et al:Vaccines sixth edition (Plotkin SA, Orenstein WA, Offit PA, eds), Elsevier, Philadelphia, p284, 2013
8)Centers for Disease Control and Prevention (CDC):Influenza (Flu)(https://www.cdc.gov/flu/prevent/prevention.htm)(最終アクセス:2022年2月27日)
9)日本環境感染学会ワクチン委員会:医療関係者のためのワクチンガイドライン(第3版).日環境感染会誌 35(Suppl.Ⅱ):i-ii,S1-S31,2020
10)Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC):Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60(RR-7):1-45,2011